nivolumab,ipilimumab
bms
['niche-2']
#esmo22 presidential symposium 2 imposing presentation by with the phenomenal results of the niche-2 study evaluating neoadjuvant ici in locally advanced mmr-deficient colon cancer 
Postdoctoral GU Oncology Research Fellow @DanaFarber | MD, Class of 2020 @USJLiban | Interested in Oncology